Related references
Note: Only part of the references are listed.A phase I dose-escalation study of the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of the novel cyclin-dependent kinase inhibitor SCH 727965 administered every 3 weeks in subjects with advanced malignancies
G. I. Shapiro et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours
D. S. Boss et al.
ANNALS OF ONCOLOGY (2010)
A Synthetic Lethal Interaction between K-Ras Oncogenes and Cdk4 Unveils a Therapeutic Strategy for Non-small Cell Lung Carcinoma
Marta Puyol et al.
CANCER CELL (2010)
Mitigation of hematologic radiation toxicity in mice through pharmacological quiescence induced by CDK4/6 inhibition
Soren M. Johnson et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Phase I and Pharmacologic Study of SNS-032, a Potent and Selective Cdk2, 7, and 9 Inhibitor, in Patients With Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma
Wei-Gang Tong et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor
David Parry et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases
Kamil Paruch et al.
ACS MEDICINAL CHEMISTRY LETTERS (2010)
Phase I Study of Flavopiridol with Oxaliplatin and Fluorouracil/Leucovorin in Advanced Solid Tumors
Dana Rathkopf et al.
CLINICAL CANCER RESEARCH (2009)
Retinoblastoma Tumor Suppressor Gene Expression Determines the Response to Sequential Flavopiridol and Doxorubicin Treatment in Small-Cell Lung Carcinoma
Tulin Budak-Alpdogan et al.
CLINICAL CANCER RESEARCH (2009)
Pharmacodynamic Effects of Seliciclib, an Orally Administered Cell Cycle Modulator, in Undifferentiated Nasopharyngeal Cancer
Wen-Son Hsieh et al.
CLINICAL CANCER RESEARCH (2009)
Seliciclib in malignancies
Ibrahim T. Aldoss et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2009)
Human CtIP Mediates Cell Cycle Control of DNA End Resection and Double Strand Break Repair
Pablo Huertas et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Overall Cdk activity modulates the DNA damage response in mammalian cells
Antonio Cerqueira et al.
JOURNAL OF CELL BIOLOGY (2009)
Cdk1 Participates in BRCA1-Dependent S Phase Checkpoint Control in Response to DNA Damage
Neil Johnson et al.
MOLECULAR CELL (2009)
CtIP-BRCA1 modulates the choice of DNA double-strand-break repair pathway throughout the cell cycle
Maximina H. Yun et al.
NATURE (2009)
Phosphorylation of ATM by Cdk5 mediates DNA damage signalling and regulates neuronal death
Bo Tian et al.
NATURE CELL BIOLOGY (2009)
Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells
Jan J. Molenaar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Flavopiridol in Chronic Lymphocytic Leukemia: A Concise Review
Beth A. Christian et al.
CLINICAL LYMPHOMA & MYELOMA (2009)
Cell cycle, CDKs and cancer: a changing paradigm
Marcos Malumbres et al.
NATURE REVIEWS CANCER (2009)
Toxicity and toxicokinetics of the cyclin-dependent kinase inhibitor AG-024322 in cynomolgus monkeys following intravenous infusion
Alan P. Brown et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
The cyclin-dependent kinase inhibitor flavopiridol potentiates the effects of topoisomerase I poisons by suppressing rad51 expression in a p53-dependent manner
Grazia Arnbrosini et al.
CANCER RESEARCH (2008)
Familial breast cancers without mutations in BRCA1 or BRCA2 have low cyclin E and high cyclin D1 in contrast to cancers in BRCA mutation carriers
Kirsimari Aaltonen et al.
CLINICAL CANCER RESEARCH (2008)
A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor
Nicholas C. Turner et al.
EMBO JOURNAL (2008)
Control of DNA polymerase lambda stability by phosphorylation and ubiquitination during the cell cycle
Ursula Wimmer et al.
EMBO REPORTS (2008)
Cell cycle-dependent complex formation of BRCA1.CtIP.MRN is important for DNA double-strand break repair
Longchuan Chen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Expanded roles for Chk1 in genome maintenance
Greg H. Enders
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
A synthetic lethal therapeutic approach: Poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair
Alan Ashworth
JOURNAL OF CLINICAL ONCOLOGY (2008)
Flavopiridol displays preclinical activity in acute lymphoblastic leukemia
Kelly M. Jackman et al.
PEDIATRIC BLOOD & CANCER (2008)
Sequential and synergistic modification of human RPA stimulates chromosomal DNA repair
Rachel W. Anantha et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Human CtIP promotes DNA end resection
Alessandro A. Sartori et al.
NATURE (2007)
Cdk1 is sufficient to drive the mammalian cell cycle
David Santamaria et al.
NATURE (2007)
Functional consequences of cyclin D1/BRCA1 interaction in breast cancer cells
K. Kehn et al.
ONCOGENE (2007)
Cyclin-dependent kinase 2-dependent phosphorylation of ATRIP regulates the G2-M checkpoint response to DNA damage
Jeremy S. Myers et al.
CANCER RESEARCH (2007)
The antiapoptotic protein Mcl-1 is essential for the survival of neutrophils but not macrophages
Ivan Dzhagalov et al.
BLOOD (2007)
A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days
C. Benson et al.
BRITISH JOURNAL OF CANCER (2007)
Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells
Dongpo Cai et al.
CANCER RESEARCH (2006)
Differential usage of non-homologous end-joining and homologous recombination in double strand break repair
Eiichiro Sonoda et al.
DNA REPAIR (2006)
Cyclin-dependent kinase 2 functions in normal DNA repair and is a therapeutic target in BRCA1-deficient cancers
Andrew J. Deans et al.
CANCER RESEARCH (2006)
Controlling the elongation phase of transcription with P-TEFb
B. Matija Peterlin et al.
MOLECULAR CELL (2006)
Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1
Lyubomir T. Vassilev et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Unmasking the redundancy between Cdk1 and Cdk2 at G2 phase in human cancer cell lines
Lawrence L'Italien et al.
CELL CYCLE (2006)
Cyclin-dependent kinase pathways as targets for cancer treatment
GI Shapiro
JOURNAL OF CLINICAL ONCOLOGY (2006)
BRCA1 at the crossroad of multiple cellular pathways: approaches for therapeutic interventions
Ronit I. Yarden et al.
MOLECULAR CANCER THERAPEUTICS (2006)
ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks
A Jazayeri et al.
NATURE CELL BIOLOGY (2006)
p53 in recombination and repair
S. A. Gatz et al.
CELL DEATH AND DIFFERENTIATION (2006)
Roscovitine modulates DNA repair and senescence: Implications for combination chemotherapy
E Crescenzi et al.
CLINICAL CANCER RESEARCH (2005)
Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death
R Chen et al.
BLOOD (2005)
Human CDK2 inhibition modifies the dynamics of chromatin-bound minichromosome maintenance complex and replication protein A
YH Zhu et al.
CELL CYCLE (2005)
Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points
KC Bible et al.
CLINICAL CANCER RESEARCH (2005)
Induction of apoptosis by flavopiridol unrelated to cell cycle arrest in germ cell tumour derived cell lines
F Mayer et al.
INVESTIGATIONAL NEW DRUGS (2005)
A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol
MA Shah et al.
CLINICAL CANCER RESEARCH (2005)
Cyclin E expression in breast cancer:: predicting germline BRCA1 mutations, prognosis and response to treatment
PO Chappuis et al.
ANNALS OF ONCOLOGY (2005)
In my end is my beginning: control of end resection and DSBR pathway 'choice' by cyclin-dependent kinases
R Scully et al.
ONCOGENE (2005)
Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6
PL Toogood et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
CDK-dependent phosphorylation of BRCA2 as a regulatory mechanism for recombinational repair
F Esashi et al.
NATURE (2005)
Phosphorylation of human DNA polymerase lambda by the cyclin-dependent kinase Cdk2/cyclin A complex is modulated by its association with proliferating cell nuclear antigen
I Frouin et al.
NUCLEIC ACIDS RESEARCH (2005)
N-(Cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase -: 2.: N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent
RN Misra et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Coordination of transcription, RNA processing, and surveillance by P-TEFb kinase on heat shock genes
ZY Ni et al.
MOLECULAR CELL (2004)
Cellular control of gene expression by T-type cyclin/CDK9 complexes
J Garriga et al.
GENE (2004)
Intra-S-phase checkpoint activation by direct CDK2 inhibition
YH Zhu et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF
JY Du et al.
CANCER CELL (2004)
Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol
GI Shapiro
CLINICAL CANCER RESEARCH (2004)
P53′s double life:: transactivation-independent repression of homologous recombination
P Bertrand et al.
TRENDS IN GENETICS (2004)
DNA end resection, homologous recombination and DNA damage checkpoint activation require CDK1
G Ira et al.
NATURE (2004)
Elongation by RNA polymerase II: the short and long of it
RJ Sim et al.
GENES & DEVELOPMENT (2004)
Proteasome-mediated destruction of the cyclin A/cyclin-dependent kinase 2 complex suppresses tumor cell growth in vitro and in vivo
W Chen et al.
CANCER RESEARCH (2004)
Flavopiridol induces p53 via initial inhibition of Mdm2 and p21 and, independently of p53, sensitizes apoptosis-reluctant cells to tumor necrosis factor
ZN Demidenko et al.
CANCER RESEARCH (2004)
The cyclin A1-CDK2 complex regulates DNA double-strand break repair
C Müller-Tidow et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
Cdk2 knockout mice are viable
C Berthet et al.
CURRENT BIOLOGY (2003)
Regulation and mechanisms of mammalian double-strand break repair
K Valerie et al.
ONCOGENE (2003)
Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice
S Ortega et al.
NATURE GENETICS (2003)
Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes
L Zou et al.
SCIENCE (2003)
A subset of ATM- and ATR-dependent phosphorylation events requires the BRCA1 protein
N Foray et al.
EMBO JOURNAL (2003)
Molecular views of recombination proteins and their control
SC West
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2003)
Chk1 and Chk2 kinases in checkpoint control and cancer
J Bartek et al.
CANCER CELL (2003)
Proliferation of cancer cells despite CDK2 inhibition
O Tetsu et al.
CANCER CELL (2003)
In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine)
SJ McClue et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Complexities in the development of cyclin-dependent kinase inhibitor drugs
EA Sausville
TRENDS IN MOLECULAR MEDICINE (2002)
Cell cycle checkpoint signaling through the ATM and ATR kinases
RT Abraham
GENES & DEVELOPMENT (2001)
Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo
SH Chao et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Mechanisms of action of flavopiridol
HH Sedlacek
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2001)
Flavopiridol inhibits P-TEFb and blocks HIV-1 replication
SH Chao et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro
S Matsuoka et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Share Paper
